Studies cancer risk in families with inherited bone marrow failure syndromes
Follows families with inherited bone marrow failure to learn which cancers occur.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Bethesda and Rockville, United StatesSee the 2 sites
- Trial code
- Registry title
- Cancer in Inherited Bone Marrow Failure Syndromes
- Status
- Recruiting
- People taking part
- 4,000 people, planned
- Started
- 28 Nov 2001
- Type of study
- Observational
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with an inherited bone marrow failure syndrome (the bone marrow does not make enough blood cells) and their family members. It also takes some people with certain cancers who have no usual risk factors.
- Age
- From 1 Day to 100 Years.
- Sex
- All sexes.
- Disease stage
- Inherited bone marrow failure syndromes, such as Fanconi anemia, Diamond Blackfan anemia, dyskeratosis congenita, Shwachman Diamond Syndrome, amegakaryocytic thrombocytopenia, thrombocytopenia absent radii, severe congenital neutropenia, Pearson Syndrome or others. Family members (siblings, biologic parents, children, grandparents) can also join. People with head and neck, gastrointestinal or anogenital cancer with no usual risk factors (such as smoking, drinking, HPV) can be checked for these syndromes.
- Biomarker or test result
- The syndrome may be suspected from body features, or confirmed by a harmful gene change in a bone marrow failure gene or by a clinical test.
Main reasons for not taking part
- The blood disorder was acquired, not inherited, for example caused by drugs, chemicals, toxins or viruses.
- Low blood counts with another known cause, such as autoantibodies, hepatitis or low vitamins or minerals.
- Physical findings explained by another syndrome outside this group.
- Family members cannot join if no one in the family has the syndrome.
- Unable to sign consent, or unwilling to allow access to medical records and tissue samples.
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Fanconi s anemia
- Diamond Blackfan anemia
- Dyskeratosis congenita
- Shwachman Diamond Syndrome
- Amegakaryocytic thrombocytopenia
- Thrombocytopenia absent radii
- Severe Congenital Neutropenia
- Pearson Syndrome
- Other bone marrow failure syndromes; Family Members of IBMFS - Affected Subjects:; -Family members include first degree relatives of IBMFS-affected subjects as defined here, i.e. siblings (half or full), biologic parents, and children. Grandparents of IBMFS-affected subjects are also included, specifically for Hypothesis 4. The age range will be from birth to old age (grandparents of probands); Patients in the general population:; -Patients in the general population with sporadic tumors of the types seen in the IBMFS (head and neck, gastrointestinal, and anogenital cancer), with none of the usual risk factors for those tumors (e.g. smoking, drinking, HPV). These patients will be further evaluated for an IBMFS by the referring physician under the guidance of the study investigators and if diagnosed with an IBMFS or if not diagnosed but highly suspicious for an IBMFS, would be eligible for inclusion in the Field and Clinic Center cohorts
Who cannot take part
- Evidence that the hematologic disorder is acquired rather than genetic. Such evidence includes temporal relation of the aplastic anemia to known marrow suppressant drugs, chemicals, toxins, or viruses (in the absence of evidence indicative of an inherited marrow failure disorder)
- Assignment of the patient s physical findings to other syndromes or causes that are not part of the IBMFS disease spectrum
- Unwillingness to permit access to medical records and pathology specimens; There are no other exclusion parameters not related to the primary disease; -Unaffected/Family Members: An individual who meets any of the following criteria will be excluded from participation in this study:
- Known causes of cytopenias such as autoantibodies to red cells, platelets, or neutrophils, viruses (especially hepatitis), micronutrient deficiencies, transient erythroblastopenia of childhood, and cyclic neutropenia
- -Affected: An individual who meets any of the following criteria will be excluded from participation in this study:
- Inability of the participant or LAR to understand and be willing to sign a written informed consent document
- If there is no affected individual in the family who meets the inclusion criteria
- Inability of the participant or LAR to understand and be willing to sign a written informed consent document
- Unwillingness to permit access to medical records and pathology specimens
Other criteria
- INCLUSION CRITERIA:; The participants will be affected by an IBMFS, or be members of a family with an IBMFS, and be at risk of being affected or carriers of the syndrome. Except for the rare X-linked recessive disorder (e.g. some dyskeratosis congenita patients), there should be equal numbers of male and female probands and family members. These IBMFS have been reported in most racial and ethnic groups, and thus all such groups will be included. The age range will be from birth to old age (grandparents of probands). The majority of the probands will be children (10-20% will be adults), and their parents and grandparents will be adults. All racial/ethnic groups are eligible
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: NCI Family Study ReferralsTaking people
- National Cancer Institute - Shady GroveRockville, United StatesContact: NCI Family Study ReferralsTaking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders.
Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers.
Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer.
These cancer-prone families are well suited for cancer screening and prevention trials targeting those at increased genetic risk of cancer.
Carriers of IBMFS pathogenic variant(s) are at increased risk of cancer.
The prototype disorder is Fanconi's Anemia (FA); other IBMFS will also be studied.
Objectives:
To determine the types and incidence of specific cancers in patients with an IBMFS.
To investigate the relevance of IBMFS pathogenic variant(s) in the carcinogenesis pathway of the sporadic counterparts of IBMFS-associated cancers.
To identify risk factors for IBMFS-related cancers in addition to the primary germline pathogenic variant(s).
To determine the risk of cancer in IBMFS carriers.
Eligibility:
North American families with a proband with an IBMFS.
IBMFS suspected by phenotype, confirmed by pathogenic variant(s) in an IBMFS gene, or by clinical diagnostic test.
Fanconi's anemia: birth defects, marrow failure, early onset malignancy; positive chromosome breakage result.
Diamond-Blackfan anemia: pure red cell aplasia; elevated red cell adenosine deaminase.
Dyskeratosis congenita: dysplastic nails, lacey pigmentation, leukoplakia; marrow failure.
Shwachman-Diamond Syndrome: malabsorption; neutropenia.
Amegakaryocytic thrombocytopenia: early onset thrombocytopenia.
Thrombocytopenia absent radii: absent radii; early onset thrombocytopenia.
Severe Congenital Neutropenia: neutropenia, pyogenic infections, bone marrow maturation arrest.
Pearson's Syndrome: malabsorption, neutropenia, marrow failure, metabolic acidosis; ringed sideroblasts.
Other bone marrow failure syndromes: e.g. Revesz Syndrome, WT, IVIC, radio-ulnar synostosis, ataxia-pancytopenia.
First degree relatives of IBMFS-affected subjects as defined here, i.e. siblings (half or full), biologic parents, and children.
Grandparents of IBMFS-affected subjects.
Patients in the general population with sporadic tumors of the types seen in the IBMFS (head and neck, gastrointestinal, and anogenital cancer), with none of the usual risk factors (e.g. smoking, drinking, HPV).
Design:
Natural history study, with questionnaires, clinical evaluations, clinical and research laboratory test, review of medical records, cancer surveillance.
Primary endpoints are all cancers, solid tumors, and cancers specific to each type of IBMFS.
Secondary endpoints are markers of pre-malignant conditions, such as leukoplakia, serum or tissue evidence of carcinogenic viruses, and bone marrow morphologic myelodyplastic syndrome or cytogenetic clones....
The group in the trial
- 1
All families with a member who has one of the relevant syndromes.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
- Plain-language title
- Studies cancer risk in families with inherited bone marrow failure syndromesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Avascular Necrosis and Minimal Trauma Fractures in Telomere Biology Disorders.Clinical genetics, 2026
- Germline RTEL1 Variants in Telomere Biology Disorders.American journal of medical genetics. Part A, 2025
- The incidence and spectrum of congenital hand differences in patients with Fanconi anaemia: analysis of 48 patients.The Journal of hand surgery, European volume, 2022
- Pathogenic germline IKZF1 variant alters hematopoietic gene expression profiles.Cold Spring Harbor molecular case studies, 2021
- Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.Cells, 2021
- Expansion of germline RPS20 mutation phenotype to include Diamond-Blackfan anemia.Human mutation, 2020
- Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up.Haematologica, 2018
- Novel and known ribosomal causes of Diamond-Blackfan anaemia identified through comprehensive genomic characterisation.Journal of medical genetics, 2017
- Record updated
- 12 November 2026